Your browser doesn't support javascript.
loading
Rhabdomyolysis in a patient taking nebivolol
Kidney Research and Clinical Practice ; : 182-186, 2016.
Article in English | WPRIM | ID: wpr-198725
ABSTRACT
β Blockers such as propranolol and labetalol are known to induce toxic myopathy because of their partial β₂ adrenoceptor agonistic effect. Nebivolol has the highest β1 receptor affinity among β blockers, and it has never been reported to induce rhabdomyolysis until now. We report a patient who developed rhabdomyolysis after changing medication to nebivolol. A 75-year-old woman was admitted to our hospital because of generalized weakness originating 2 weeks before visiting. Approximately 1 month before her admission, her medication was changed from carvedilol 12.5 mg to nebivolol 5 mg. Over this time span, she had no other lifestyle changes causing rhabdomyolysis. Her blood chemistry and whole body bone scan indicated rhabdomyolysis. We considered newly prescribed nebivolol as a causal agent. She was prescribed carvedilol 12.5 mg, which she was previously taking, instead of nebivolol. She was treated by hydration and urine alkalization. She had fully recovered and was discharged.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Propranolol / Rhabdomyolysis / Chemistry / Nebivolol / Labetalol / Life Style / Muscular Diseases Limits: Aged / Female / Humans Language: English Journal: Kidney Research and Clinical Practice Year: 2016 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Propranolol / Rhabdomyolysis / Chemistry / Nebivolol / Labetalol / Life Style / Muscular Diseases Limits: Aged / Female / Humans Language: English Journal: Kidney Research and Clinical Practice Year: 2016 Type: Article